3 Summary of NICE recommendations

3 Summary of NICE recommendations

NICE guidance on the use of Spectra Optia for automated red cell exchange in people with sickle cell disease who need regular transfusions recommends that the case for adoption is supported by the evidence. Cost modelling shows that in most cases, using Spectra Optia is cost saving compared with manual red blood cell exchange or top‑up transfusion. The guidance recommends collaborative data collection to supplement the clinical evidence on some outcomes of treatment with Spectra Optia, in particular long‑term data on how automated and manual exchange affects iron overload status and the subsequent need for chelation therapy.


This page was last updated: 02 March 2016